Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Nd multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant therapy (DFS, MFS and OS; all, P
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
Nd multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant therapy (DFS, MFS and OS; all, P
Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Antitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005 (mRNA levels relative to reference gene set). bInteraction with continuous DC-SCRIPT (P
Early breast cancer. The patients described in thisSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 7 ofTable 3 Disease-free survival, metastasis-free survival, and overall survival as a function of continuous DC-SCRIPT in lymph node-negative diseaseAssociation with continuous DC-SCRIPT Cohort Lymph node-negative ESR1 mRNA-negativea ESR1 mR
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0